The role of XXXX in combination chemotherapy for the treatment of @entity706 : retrospective study of the Intergruppo Italiano Linfomi on 761 cases.

@entity1 @entity8253 @entity706 @entity4349 @entity177 @entity1349
In order to elucidate the role of @entity4349 based combination chemotherapy regimens for the treatment of @entity706 we conducted a retrospective study on a large series of @entity1 with a histologically confirmed diagnosis of @entity706 . The @entity706 intergroup (ILI) promoted a retrospective study of @entity1 with @entity706 treated in cooperative trials between 1985 and 1996. Six hundred and thirty three cases were treated with an @entity4349 -containing regimen and 128 @entity1 were treated without @entity8253 . The two groups were prognostically comparable; in particular, no difference was observed according to both IPI and ILI prognostic index. Results showed a complete remission (CR) rate for @entity1 treated with @entity8253 was 69.2% and overall response rate was 92.5%. After a median follow-up of 51 months (54 months for @entity1 still alive), the 5- and 10-year @entity1349 ( @entity1349 ) rates were 80 and 66%, respectively. Disease-free survival (DFS) and @entity177 ( @entity177 ) rates at 5 years were 61 and 49%, respectively. In the group of @entity1 treated with combination chemotherapy not including @entity8253 , the CR rate was 67.5% and the overall response rate was 85.4%. A longer @entity1349 (80% at 5 years) was observed in @entity1 treated with @entity8253 compared to 67% @entity1349 rate in @entity1 treated without @entity8253 (p = 0.0004). @entity177 was significantly longer in @entity1 treated with @entity8253 (49 vs. 34% p = 0.006). @entity1 treated with @entity8253 with low or intermediate risk according to ILI prognostic index showed a significantly longer @entity1349 (p = 0.0001 andp = 0.0009, respectively); those in the high-risk group showed a trend for a longer survival. In conclusion, this retrospective study shows that @entity1 with @entity706 treated with an @entity4349 containing regimen had a better outcome compared to @entity1 treated with other combination regimens non including @entity8253 in terms of CRs, @entity1349 and @entity177 . On the basis of these results @entity4349 -containing regimens (ACR) should be considered as the standard treatment of @entity1 with advanced @entity706 .
